CGTLive Staff
Articles
Takeaways From Phase 1 Trial of RTX-240 in Solid Tumors: Alexander I. Spira, MD, PhD, FACP
May 10th 2022Alexander I. Spira, MD, PhD, FACP, research institute director with Virginia Cancer Specialists Research Institute, discusses the examination of RTX-240 in a phase 1 trial (NCT04372706) with solid tumors, presented recently at the 2022 AACR Annual Meeting.
Opportunities for CAR T-Cell Therapy in Solid Tumors
May 6th 2022Radek Špíšek, PhD, co-founder and chief executive officer of SOTIO Global, and Geoffrey Hodge, chief executive officer of SOTIO BioTech US, join CGTL to discuss its 3 technology platforms and how they are leveraging them to attack the solid tumor micro-environment.
Keeping Patients at the Center of CAR T-Cell Therapy Development: Jennifer Chow
April 29th 2022The CEO and managing director of Chimeric Therapeutics hopes to contribute to the narrative with a handful of offerings in development across 2 platforms: CORE-NK, which uses allogeneic natural killer cells, and T-cell derived autologous therapies.
